{"schema_version":"1.0","type":"article","title":"Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?","url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.md","lang":"en","date":"2026-10-04","publish_at":"2026-10-04T08:00:00+08:00","updated_at":"2026-10-04","category":"商業分析系列","topic":"商業分析系列","tags":["LUNA","atogepant","AbbVie","CGRP","偏頭痛"],"summary":"The days around menstruation can already be uncomfortable. Add migraine, sensitivity to light or nausea, and work, school pickups and carefully planned activities can be disrupted. For people whose attacks repeatedly cluster in this window, the question is straightforward: can the burden be reduced before the headache arrives?","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"A woman and calendar identify the risk window around menstruation; the seven-day preventive study regimen connects to migraine diaries and daily-function assessments.","url":"https://drugnews.com.tw/assets/articles/luna-atogepant-menstrual-migraine-2026-en/FIG01_EN_R3.png"},{"alt":"Atogepant blockade of the CGRP receptor is shown above separate, non-scale descriptions of seven-day dosing scheduled from anticipated menstruation and PMP assessment defined relative to menstrual onset. The two do not share a proportional timeline.","url":"https://drugnews.com.tw/assets/articles/luna-atogepant-menstrual-migraine-2026-en/FIG02_EN_R4.png"},{"alt":"Perimenstrual periods (PMPs) across three cycles lead to the mean change in migraine days. Atogepant and placebo show reductions of 1.20 and 0.40 days, with a separate 0.80-day between-group difference and P<0.0001.","url":"https://drugnews.com.tw/assets/articles/luna-atogepant-menstrual-migraine-2026-en/FIG03_EN_R5.png"},{"alt":"A woman holding a pen sits at the center with a diary labeled “My diary”; lines connect her to four surrounding panels. Upper left, “Functional impact,” includes a laptop and house icon and states that the company reports functional secondary endpoints met while full effect sizes await disclosure. Upper right, “Acute medication use,” includes a medication record. Lower left, “Adverse events and tolerability,” includes an adverse-event record and warning symbol. Lower right, “Continued use,” includes a calendar and describes use across menstrual cycles.","url":"https://drugnews.com.tw/assets/articles/luna-atogepant-menstrual-migraine-2026-en/FIG04_EN_R3.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/luna-atogepant-menstrual-migraine-2026-en/FIG01_EN_R3.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-04）。Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?。https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-10-04-luna-atogepant-menstrual-migraine-2026.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}